Side-by-side · Research reference
GlutathionevsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED6/39 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
Glutathione
Endogenous Tripeptide · Antioxidant
IV · Oral · Inhaled
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
Glutathione
Humanin
Primary target
Intracellular redox systems, glutathione peroxidase, glutathione transferase
Pathway
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
—
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
Glutathione
Humanin
Endogenous synthesis
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
—
Exogenous oral
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
—
IV supplementation
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
—
Precursor strategy
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
—
Evidence basis
Animal mechanistic + human mechanistic
Animal models (rat, mouse)Huang 2025El 2022Velentza 2024
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Frequency
—
Daily (IP)
Duration
—
8–12 weeks in animal studies
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
Glutathione
Humanin
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
Glutathione
Humanin
Oral supplementation
GI discomfort, bloating (mild, dose-dependent)
—
IV administration
Rare hypersensitivity, infusion site reaction
—
Inhalation
Bronchospasm risk in asthma (rare)
—
Tumor metabolism
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Human safety data
—
None — no clinical trials
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Injection site reaction
—
Not reported in animal studies (IP route)
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
Glutathione
—Humanin
- ·Unknown — no human data
Relative Contraindications
Glutathione
- ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
- ·Severe asthma (inhaled formulations)
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
Glutathione
Humanin
1. Oral administration
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Intravenous
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. Inhaled formulations
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
Daily administration in animal studies. Optimal timing not characterized.
4. Precursor supplementation
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Human use
—
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
Glutathione
— no documented stacks
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling